Literature DB >> 12033370

Targeted delivery of doxorubicin by HPMA copolymer-hyaluronan bioconjugates.

Yi Luo1, Nicole J Bernshaw, Zheng-Rong Lu, Jindrich Kopecek, Glenn D Prestwich.   

Abstract

PURPOSE: Overexpression of hyaluronan (HA) receptors on cancer cells results in enhanced endocytotic uptake of the drug conjugate. An N-(2-hydroxypropyl)methacrylamide (HPMA)-HA polymeric drug delivery system was used for targeted delivery of doxorubicin to cancer cells.
METHODS: HA-doxorubicin (DOX) bioconjugates (HA-DOX), and HPMA copolymer-DOX conjugates containing HA as a side chain (HPMA-HA-DOX) were synthesized. The cytotoxicity of the polymer-drug conjugate was evaluated via in vitro cell culture. The internalization of the conjugate was visualized by fluorescence microscopy.
RESULTS: Cytotoxicity of HPMA-HA-DOX targeted bioconjugate was higher against human breast cancer (HBL-100), ovarian cancer (SKOV-3), and colon cancer (HCT-116) cells when compared to the non-targeted HPMA-DOX conjugate. Fluorescence confocal microscopy revealed that the targeted HPMA-HA-DOX conjugates were internalized more efficiently by cancer cells relative to the non-targeted HPMA-DOX conjugate. Both HPMA-DOX and HPMA-HA-DOX showed minimal cytotoxicity toward mouse fibroblast NIH 3T3 cells. The internalization of polymer conjugates was correlated with their cytotoxicity.
CONCLUSIONS: Selective delivery of anti-cancer agents to cancer cells was achieved by biochemical targeting. The HA-modified HPMA copolymer showed improved toxicity due to receptor-mediated uptake of the macromolecular drug.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12033370     DOI: 10.1023/a:1015170907274

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  26 in total

1.  Expression of hyaluronan receptors CD44 and RHAMM in stomach cancers: relevance with tumor progression.

Authors:  H Li; L Guo; J W Li; N Liu; R Qi; J Liu
Journal:  Int J Oncol       Date:  2000-11       Impact factor: 5.650

2.  CD44 interaction with tiam1 promotes Rac1 signaling and hyaluronic acid-mediated breast tumor cell migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Biol Chem       Date:  2000-01-21       Impact factor: 5.157

3.  Preliminary clinical study of the distribution of HPMA copolymers bearing doxorubicin and galactosamine.

Authors:  P J Julyan; L W Seymour; D R Ferry; S Daryani; C M Boivin; J Doran; M David; D Anderson; C Christodoulou; A M Young; S Hesslewood; D J Kerr
Journal:  J Control Release       Date:  1999-02-22       Impact factor: 9.776

4.  Binding and degradation of hyaluronan by human breast cancer cell lines expressing different forms of CD44: correlation with invasive potential.

Authors:  M Culty; M Shizari; E W Thompson; C B Underhill
Journal:  J Cell Physiol       Date:  1994-08       Impact factor: 6.384

5.  Cell-based screen for identification of inhibitors of tubulin polymerization.

Authors:  J M Kokoshka; C M Ireland; L R Barrows
Journal:  J Nat Prod       Date:  1996-12       Impact factor: 4.050

6.  A hyaluronic acid-taxol antitumor bioconjugate targeted to cancer cells.

Authors:  Y Luo; M R Ziebell; G D Prestwich
Journal:  Biomacromolecules       Date:  2000       Impact factor: 6.988

7.  Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill.

Authors:  M B Hansen; S E Nielsen; K Berg
Journal:  J Immunol Methods       Date:  1989-05-12       Impact factor: 2.303

8.  Perturbation of hyaluronan interactions by soluble CD44 inhibits growth of murine mammary carcinoma cells in ascites.

Authors:  R M Peterson; Q Yu; I Stamenkovic; B P Toole
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

9.  Antibody-directed affinity therapy applied to the immune system: in vivo effectiveness and limited toxicity of daunomycin conjugated to HPMA copolymers and targeting antibody.

Authors:  B Ríhová; P Kopecková; J Strohalm; P Rossmann; V Vĕtvicka; J Kopecek
Journal:  Clin Immunol Immunopathol       Date:  1988-01

10.  Phase I clinical and pharmacokinetic study of PK1 [N-(2-hydroxypropyl)methacrylamide copolymer doxorubicin]: first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee.

Authors:  P A Vasey; S B Kaye; R Morrison; C Twelves; P Wilson; R Duncan; A H Thomson; L S Murray; T E Hilditch; T Murray; S Burtles; D Fraier; E Frigerio; J Cassidy
Journal:  Clin Cancer Res       Date:  1999-01       Impact factor: 12.531

View more
  27 in total

1.  Polyaspartamide-doxorubicin conjugate as potential prodrug for anticancer therapy.

Authors:  Chiara Di Meo; Felisa Cilurzo; Mariano Licciardi; Cinzia Scialabba; Rocchina Sabia; Donatella Paolino; Donatella Capitani; Massimo Fresta; Gaetano Giammona; Claudio Villani; Pietro Matricardi
Journal:  Pharm Res       Date:  2014-10-31       Impact factor: 4.200

2.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

3.  Mechanism-based tumor-targeting drug delivery system. Validation of efficient vitamin receptor-mediated endocytosis and drug release.

Authors:  Shuyi Chen; Xianrui Zhao; Jingyi Chen; Jin Chen; Larisa Kuznetsova; Stanislaus S Wong; Iwao Ojima
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

Review 4.  Can nanomedicines kill cancer stem cells?

Authors:  Yi Zhao; Daria Y Alakhova; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2013-10-10       Impact factor: 15.470

5.  Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.

Authors:  Xin Wei; Thulani H Senanayake; Galya Warren; Serguei V Vinogradov
Journal:  Bioconjug Chem       Date:  2013-04-02       Impact factor: 4.774

6.  Hyaluronan-based nanocarriers with CD44-overexpressed cancer cell targeting.

Authors:  Shuangshuang Song; Huan Qi; Jingwen Xu; Pan Guo; Fen Chen; Fei Li; Xinggang Yang; Naicheng Sheng; Yingliang Wu; Weisan Pan
Journal:  Pharm Res       Date:  2014-05-20       Impact factor: 4.200

Review 7.  Application of polysaccharides for surface modification of nanomedicines.

Authors:  Kyung-Oh Doh; Yoon Yeo
Journal:  Ther Deliv       Date:  2012-12

8.  Biomimetic Material-Assisted Delivery of Human Embryonic Stem Cell Derivatives for Enhanced In Vivo Survival and Engraftment.

Authors:  Harsha Kabra; Yongsung Hwang; Han Liang Lim; Mrityunjoy Kar; Gaurav Arya; Shyni Varghese
Journal:  ACS Biomater Sci Eng       Date:  2015-01-12

9.  Hyaluronic acid derivative-based self-assembled nanoparticles for the treatment of melanoma.

Authors:  Yu-Jin Jin; Ubonvan Termsarasab; Seung-Hak Ko; Jae-Seong Shim; Saeho Chong; Suk-Jae Chung; Chang-Koo Shim; Hyun-Jong Cho; Dae-Duk Kim
Journal:  Pharm Res       Date:  2012-08-11       Impact factor: 4.200

Review 10.  Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come.

Authors:  Phatsapong Yingchoncharoen; Danuta S Kalinowski; Des R Richardson
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.